Mark Corrigan has an estimated net worth of $11.7 Million. This is based on reported shares across multiple companies, which include Nabriva Therapeutics Plc, CoLucid Pharmaceuticals, Inc., Nabriva Therapeutics plc, NOVELION THERAPEUTICS INC., Wave Life Sciences Ltd., TREVENA INC, CUBIST PHARMACEUTICALS INC, EPIRUS Biopharmaceuticals, Inc., AVANIR PHARMACEUTICALS, INC., and SEPRACOR INC /DE/.

2004 was Mark Corrigan's most active year for acquiring shares with 13 total transactions. Mark Corrigan's most active month to acquire stocks was the month of May. 2007 was Mark Corrigan's most active year for disposing of shares, totalling 72 transactions. Mark Corrigan's most active month to dispose stocks was the month of May. 2005 saw Mark Corrigan paying a total of $9,017,600.00 for 240,000 shares, this is the most they've acquired in one year. In 2007 Mark Corrigan cashed out on 351,382 shares for a total of $11,528,832.79, their largest year based on trade value.